Nov 27 (Reuters) - GSK plc:

* GSK PLC - GSK ANNOUNCES POSITIVE DREAMM-7 HEADLINE RESULTS

* GSK PLC - GSK ANNOUNCES POSITIVE DREAMM-7 HEADLINE RESULTS

* GSK - GSK ANNOUNCES POSITIVE RESULTS FROM DREAMM-7 HEAD-TO-HEAD PHASE III TRIAL FOR BLENREP IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

* GSK - BLENREP (BELANTAMAB MAFODOTIN) PLUS BORDEX SHOWED STATISTICALLY SIGNIFICANT PROGRESSION-FREE SURVIVAL BENEFIT VERSUS DARATUMUMAB PLUS BORDEX

* GSK: SAFETY AND TOLERABILITY OF BELANTAMAB MAFODOTIN REGIMEN WAS CONSISTENT WITH KNOWN SAFETY PROFILE OF INDIVIDUAL AGENTS

* GSK - TRIAL UNBLINDED EARLY BASED ON INDEPENDENT DATA MONITORING COMMITTEE (IDMC) RECOMMENDATION

* GSK - DREAMM-8 DATA ARE EXPECTED IN SECOND HALF OF 2024

* GSK - DREAMM-7 PRIMARY ENDPOINT IS PROGRESSION-FREE SURVIVAL AS PER AN INDEPENDENT REVIEW COMMITTEE Source text for Eikon: Further company coverage: